Phase2 study of Carboplatin / Nab-paclitaxel + Bevacizumab to non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussio
Phase 2
- Conditions
- non-small-cell lung cancer (non-squamous cell carcinoma) with malignant pleural efussion in stage4
- Registration Number
- JPRN-UMIN000013329
- Lead Sponsor
- Osaka Prefectural Medical Center for Respiratory and Allergic diseases
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1)History of pleurodesis or pleural effusion drainage 2)Severe infection except for non-active hepatitis C 3)Fever more than 38 degree 4)Severe comorbidity (heart failure/kidney failure/hepatic failure/uncontrollable diabetes/uncontrollable hypertension, etc) 5)Active double cancer 6)Symptomatic brain metastasis 7)History of hemoptysis with 2.5mL or more 8)Pericardial effusion requiring drainage 9)Interstitial pneumonia or pulmonary fibrosis detectable on X ray 10)History of drug sensitivity 11)Pregnant or lactating women 12)Psychiatric disease or mental trouble 13)Continuing administration of steroid 14)Evaluated to be ineligible by a physician for other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method efficacy
- Secondary Outcome Measures
Name Time Method Density of chest underwater VEGF before and after chemotherapy, overall survival time, safety, 1-year survival rate, progression free survival